Edwards Lifesciences Corporation $EW Position Increased by Norinchukin Bank The

Norinchukin Bank The raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 2.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 518,511 shares of the medical research company’s stock after purchasing an additional 12,228 shares during the quarter. Norinchukin Bank The owned approximately 0.09% of Edwards Lifesciences worth $40,325,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Norges Bank bought a new position in Edwards Lifesciences during the second quarter valued at approximately $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its stake in shares of Edwards Lifesciences by 111.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Edwards Lifesciences by 127.5% in the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock valued at $539,303,000 after purchasing an additional 3,864,908 shares during the last quarter. Finally, Viking Global Investors LP acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $238,688,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on EW shares. Truist Financial set a $89.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Wednesday, February 11th. BTIG Research reiterated a “buy” rating and set a $103.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Citigroup reissued a “buy” rating and set a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a report on Monday, January 12th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $96.14.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $85.93, for a total transaction of $974,446.20. Following the completion of the sale, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,827,387.38. The trade was a 34.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,371,239.08. This trade represents a 24.67% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 61,718 shares of company stock worth $5,236,281. 0.34% of the stock is owned by insiders.

Edwards Lifesciences Stock Performance

EW opened at $83.59 on Tuesday. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The business has a 50 day moving average of $82.40 and a 200-day moving average of $81.60. The stock has a market cap of $48.55 billion, a price-to-earnings ratio of 45.68, a PEG ratio of 2.13 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter last year, the company posted $0.59 EPS. The firm’s revenue was up 13.3% on a year-over-year basis. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.